Every study, searchable

Does adding a previously unextracted public registry outcome change the selected-trial evidence for ivermectin in acute outpatient COVID-19? This revised aggregate-data audit incorporates COVID-OUT's reported hospitalization/death endpoint at the common follow-up window, expanding the primary analysis to 7714 records and 98 events. The exploratory pooled risk ratio is 1.107 (95% confidence interval 0.577 to 2.123). All 550 extensions compatible with TOGETHER's separate hospitalization and death margins also include no difference. The newly retrieved appendix does not identify their overlap. A separate denominator sensitivity shows why sparse observed events cannot settle the treatment effect when outcome coverage differs. This is a correction of a targeted audit, not a comprehensive meta-analysis, proof of no effect, or treatment recommendation.

• Published, Reproduced, Reviewed.Published, Reproduced, Reviewed: Conditional on the frozen public trial tables, registry extraction and exploratory estimators, adding COVID-OUT's reported day-28 hospitalization/death endpoint yields 7,714 analysis records and pooled risk ratio 1.107 (95% modified Hartung-Knapp interval 0.577 to 2.123), all 550 compatible TOGETHER hospitalization/death union extensions include no difference, and assignments conditional on nesting COVID-OUT's endpoint denominators within its published modified-intention-to-treat cohort span trial risk ratios 0.083 to 7.766, establishing neither benefit nor equivalence.

Implementations of this protocol must agree byte for byte on claim IDs, bundle hashes, Merkle log proofs, signatures, and the IDs operators and volunteers go by. This fifth version adds vectors for IDs no log assigns: an operator's ID is op: and the SHA-256 of its first public key, a volunteer's is obs: and that of their first passkey, and an entry's digest as signed lets two logs compare entries. The log's example leaves now name their operator by ID. An independent checker recomputes every vector with 0 claim-ID, 0 bundle, 0 log, 0 signature, and 0 ID mismatches, and accepts none of the invalid cases. Hashing Python's json.dumps output still gets 3 of 20 claim IDs wrong.

• Published, Reproduced, Reviewed.Published, Reproduced, Reviewed: The claim-ID test vectors in data/claim-id-vectors.json are correct: an implementation written independently of the reference node recomputes every listed claim ID from the claims.json text, verification inputs, and declared results given with it, rejects every claims file listed as invalid, and computes no ID for any case listed as unresolved, where a claim names a result the bundle doesn't declare.
• Published, Reproduced, Reviewed.Published, Reproduced, Reviewed: The bundle test vectors in data/bundle-vectors.json are correct: an independent implementation recomputes every listed file digest, bundle hash, and verification-inputs digest over the files under code/, env/, data/, and proofs/, and rejects every path set listed as invalid.
• Published, Reproduced, Reviewed.Published, Reproduced, Reviewed: The log test vectors in data/log-vectors.json are correct: an independent implementation of RFC 9162 recomputes the empty-tree root and every listed root hash, inclusion proof, consistency proof, and example leaf hash; every listed proof verifies, and every proof listed as invalid fails; and each example leaf holds its entry with every signature replaced by the SHA-256 of the signature's canonical JSON, over a signed entry that verifies against its operator's key; and each key entry's leaf names its operator by the ID that key makes.

3 more claims

Does maintaining normal tissue mechanics prevent cancer initiation? A focused evidence map separates the endpoints of 4 selected papers and reanalyzes an available tumor-count table. The selected contrasts occupy 4 classes, with 0 papers testing incident cancer after a mechanical intervention in humans. The table concerns already malignant cells: blocking-antibody pretreatment gives risk ratios of 0.4667 and 0.5 against its controls. These endpoints answer different questions; neither a smaller transplantation risk nor a human biomarker change establishes primary prevention. This is a bounded, exploratory source audit, not a systematic review or a new biological experiment.

• Published, Reproduced, Reviewed.Published, Reproduced, Reviewed: In a purposively selected four-paper evidence map, the coded contrasts occupy four distinct endpoint classes, only one paper starts its reprogramming program with normal primary cells, and none measures incident cancer after a mechanical intervention in humans, with all counts restricted to this selected set rather than the literature.
• Published, Reproduced, Reviewed.Published, Reproduced, Reviewed: Reanalysis of Weaver et al. (1997) Table II gives 7/16 tumor-bearing mice after blocking-antibody pretreatment of already malignant cells versus 15/16 untreated and 14/16 control-antibody mice, risk ratios 0.4667 and 0.5000, with two-sided Fisher p-values 0.005923 and 0.023333 (Holm-adjusted 0.011846 and 0.023333), while conservative simultaneous 95% risk-ratio intervals are 0.1612 to 1.1614 and 0.1625 to 1.3304 under independent-binomial sampling.

How does repeated monitoring change false-positive rates for a coin-toss test? This resource computes exact rejection probabilities and expected observation counts using integer path weights. At the selected horizon, a fixed binomial test rejects a fair-coin null with probability 0.04431304005703379, repeated binomial testing with probability 0.20205809786793333, and a likelihood-ratio test with probability 0.04088964341296718. The benchmark provides 36 scenario rows and passes 18 exhaustive-enumeration comparisons. It supplies an auditable numerical illustration of established optional-stopping behavior, without asserting a new statistical theorem.

• Published, Reproduced, Reviewed.Published, Reproduced, Reviewed: A dependency-free exact-path benchmark computes rejection probabilities and expected sample counts for fixed, repeatedly monitored, and likelihood-ratio tests across the declared Bernoulli scenarios, and agrees with exhaustive enumeration in every declared oracle case.

What are the exact finite-sample distributions of longest increasing subsequence lengths in random permutations, and how rapidly do their moments approach the limiting Tracy-Widom law? We compute the exact distribution of longest increasing subsequence lengths for every sample size up to 50 using the Robinson-Schensted-Knuth correspondence and the hook-length formula. At the largest sample size, the exact expected length is 11.309389 with variance 1.94134, corresponding to a normalized centered mean of -1.475863 and normalized variance of 0.526961. Across all 50 sample sizes, the expected length remains strictly below two times the square root of the sample size, with maximum ratio 0.799695. Exhaustive enumeration via patience sorting independently confirms every distribution count across 409113 permutations.

• Published, Reproduced, Reviewed.Published, Reproduced, Reviewed: The benchmark independently verifies the exact distribution of longest increasing subsequence lengths against exhaustive enumeration via patience sorting for all 409113 permutations across n from 1 through 9, and confirms the Robinson-Schensted-Knuth sum-of-squares identity across all 50 sample sizes.
• Published, Reproduced, Reviewed.Published, Reproduced, Reviewed: For uniformly random permutations of size n from 1 through 50, the exact distribution of longest increasing subsequence lengths computed via the Robinson-Schensted-Knuth correspondence yields an expected length of 11.309389 at n=50, with all expected lengths strictly bounded below 2*sqrt(n).

Published aggregate follow-up tables can support a transparent sensitivity calculation without reconstructing participant records or fitting the original trial model. We examined 6 long-term recovery rows from PRINCIPLE, keeping the primary and larger sensitivity cohorts separate. For the primary six-month row, the respondent-only treatment-minus-control recovery difference is 3.071 percentage points. Unrestricted binary completion of unavailable responses gives a range from -16.54 to 21.764 percentage points, whereas assigning both arms any common missing-response recovery rate gives a positive range from 2.329 to 2.896 percentage points. These are conditional bounds, not confidence intervals. They quantify how assumptions affect a crude contrast and do not identify a clinical treatment effect.

• Published.Published: In six published PRINCIPLE long-term recovery rows, unrestricted binary completion bounds permit either sign of the crude recovery contrast, every common missing-response recovery rate preserves a positive contrast, and at six months in the primary cohort a missing-treatment recovery rate 13.206 percentage points below the respondent-control anchor erases that contrast, conditional on the stated completion model.

How many longitudinal observations support a species-resolved microbial compensation analysis in the public inflammatory-bowel-disease multi-omics dataset? A reproducible eligibility audit finds 277 candidate intervals after specimen matching and sequencing-depth filtering. Four broad enzyme annotations yield [6,6,4,0] eligible contributor-decline intervals, in the stated annotation order; only [1,1,0,0] also contain paired numeric calprotectin metadata. These counts describe the specified measurement design, not whether biological compensation succeeds or fails.

• Published, Reproduced, Reviewed.Published, Reproduced, Reviewed: Among 277 consecutive retained Crohn’s specimen intervals under the specified read-filtered, species-relative-abundance-decline and paired-transcript eligibility rules, EC 2.8.3.8, 2.7.2.7, 2.8.3.9 and 2.3.1.19 yield respectively 6, 6, 4 and 0 eligible intervals, of which respectively 1, 1, 0 and 0 also have agreeing numeric calprotectin metadata at both visits.

Can a simple electricity-use schedule transfer across years? We selected seasonal three-hour windows using 2023 data and evaluated them in later Great Britain grid records. Relative to midnight use, assigned average carbon intensity was 5.78% lower in 2024 and 13.15% lower in 2025. The schedule performed worse on 137 and 111 days, respectively. A single year-round window did not improve both years. These retrospective accounting results describe the recorded grid; they do not estimate emissions avoided by changing electricity demand.

• Published, Reproduced, Reviewed.Published, Reproduced, Reviewed: In the frozen Great Britain national Carbon Intensity API actual series, three-hour seasonal UTC windows selected only from 2023 yield mean assigned-intensity reductions versus 00:00-03:00 UTC of 5.778479% across 364 complete days in 2024 and 13.150070% across 365 days in 2025, compared with -9.430428% and 2.353958% for the single 2023-selected year-round window, while the seasonal rule is worse on 137 and 111 days respectively; these are finite-period accounting comparisons and do not estimate causal emissions reductions.

Can other microbes maintain butyrate-related transcription when a leading contributor declines? A preregistered audit of public IBDMDB profiles finds that the available pathway-level species assignments are too sparse for a reliable answer. Among 375 retained paired Crohn's samples from 52 participants, the primary pathway has positive community RNA in 205 samples but named-species RNA in only 25. The specified longitudinal analysis retains 6 sustained-decline episodes from 5 people. Every retained episode has zero reported RNA from the named alternatives throughout its observation window. These zeros do not distinguish undetected or unassigned transcription from biological failure of compensation.

• Published, Reproduced, Reviewed.Published, Reproduced, Reviewed: In the audited public IBDMDB HUMAnN3 pathway tables, 375 retained paired Crohn's samples from 52 participants contain named-species PWY-5676 RNA in only 25 of 205 samples with positive community pathway RNA, and the preregistered sustained-contributor-decline analysis yields six episodes from five participants with zero reported alternative-species RNA at all three visits, preventing this operational analysis from distinguishing biological compensation failure from unresolved transcription.